Sagimet Biosciences enters into $75M ATM equity sales agreement with Cantor Fitzgerald

Sagimet Biosciences Inc.

Controlled Equity Offering Sales Agreement with Cantor Fitzgerald dated August 15, 2024.
Company may sell up to $75M of Series A common stock through at-the-market offerings.
Agent entitled to commission of up to 3% of gross proceeds from each sale.
Company has no obligation to sell shares and may suspend or terminate at any time.
Registration statement on Form S-3 filed same day; sales only after SEC declares effective.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.